Zealand Pharma AS (ZLDPF)
135.65
+2.24
(+1.68%)
USD |
OTCM |
Sep 20, 16:00
Zealand Pharma Net Income (Quarterly): -42.26M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -42.26M |
| March 31, 2024 | -33.30M |
| December 31, 2023 | -38.21M |
| September 30, 2023 | 10.83M |
| June 30, 2023 | -46.70M |
| March 31, 2023 | -27.92M |
| December 31, 2022 | -47.08M |
| September 30, 2022 | -20.08M |
| June 30, 2022 | -69.93M |
| March 31, 2022 | -33.62M |
| December 31, 2021 | -43.11M |
| September 30, 2021 | -31.53M |
| June 30, 2021 | -48.10M |
| March 31, 2021 | -39.26M |
| December 31, 2020 | -60.96M |
| September 30, 2020 | -35.91M |
| June 30, 2020 | -8.592M |
| March 31, 2020 | -26.50M |
| December 31, 2019 | -28.71M |
| September 30, 2019 | -16.87M |
| June 30, 2019 | -20.63M |
| March 31, 2019 | -19.41M |
| December 31, 2018 | -19.93M |
| September 30, 2018 | 143.36M |
| June 30, 2018 | -17.67M |
| Date | Value |
|---|---|
| March 31, 2018 | -16.06M |
| December 31, 2017 | -17.38M |
| September 30, 2017 | -6.814M |
| June 30, 2017 | -13.96M |
| March 31, 2017 | -3.772M |
| December 31, 2016 | 7.157M |
| September 30, 2016 | -4.634M |
| June 30, 2016 | -14.87M |
| March 31, 2016 | -11.50M |
| December 31, 2015 | 10.09M |
| September 30, 2015 | -7.592M |
| June 30, 2015 | -11.63M |
| March 31, 2015 | -8.413M |
| December 31, 2014 | -10.57M |
| September 30, 2014 | 2.999M |
| June 30, 2014 | -8.773M |
| March 31, 2014 | 5.296M |
| December 31, 2013 | -8.170M |
| September 30, 2013 | -6.147M |
| June 30, 2013 | -8.231M |
| March 31, 2013 | -10.15M |
| December 31, 2012 | -9.123M |
| September 30, 2012 | -0.0979M |
| June 30, 2012 | 4.098M |
| March 31, 2012 | 11.58M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-69.93M
Minimum
Jun 2022
10.83M
Maximum
Sep 2023
-34.39M
Average
-34.76M
Median
Net Income (Quarterly) Benchmarks
| Novo Nordisk AS | 2.894B |
| Eli Lilly and Co | 2.967B |
| Altimmune Inc | -24.64M |
| Genmab AS | 203.24M |
| Viking Therapeutics Inc | -22.25M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 4.927M |
| Total Expenses (Quarterly) | 43.56M |
| EPS Diluted (Quarterly) | -0.6741 |
| Enterprise Value | 8.380B |
| Gross Profit Margin (Quarterly) | 72.20% |
| Profit Margin (Quarterly) | -857.7% |
| Earnings Yield | -1.25% |
| Normalized Earnings Yield | -1.009 |